Wolwopharma, founded in 1999, is a high-tech bio-pharmaceutical company specialized in R&D, production and marketing of products for the treatment and diagnosis of allergic diseases.

Its R&D center in Shanghai is in the forefront of the field and is the leading research and development center in Asia. Its GMP-compliant manufacturing facility for allergenic vaccines is the largest in Asia.

Wolwopharma also owns the most advanced bio-pharmaceutical technologies. One of the main products is “Chanllergen - Dermatophagoides farinae drops", standardized allergenic vaccine for sublingual immunotherapy. In March 2006, “Chanllergen” was approved by Chinese FDA (Approval No. S20060012). Another product ‘Spotter’, skin prick test kit, was approved by Chinese FDA in July 2008 (Approval No. S20080010). Skin prick test kit for Dermatophagoides pteronyssinus is an in-vivo skin prick test diagnostic kit, mainly for the diagnosis of the allergic diseases caused by Dermatophagoides pteronyssinus.

Wolwopharma is committed to developing the best medical products to help allergic patients for quality life worldwide. Wolwopharma also wants to bring excellent investment return to shareholders.